Valuation: Mylan Inc

Market Cap 1.9TCr 1.67TCr 1.54TCr 1.44TCr 2.7TCr 1,79800Cr 2.76TCr 18TCr 7.14TCr 89TCr 7.14TCr 6.98TCr 3,08000Cr P/E 2026 *
59.8x
P/E 2027 * 25.9x
Enterprise Value 3.12TCr 2.73TCr 2.52TCr 2.36TCr 4.43TCr 2,95000Cr 4.53TCr 30TCr 12TCr 1,45500Cr 12TCr 11TCr 5,05300Cr EV / Sales 2026 *
2.11x
EV / Sales 2027 * 2x
Free-Float
92.11%
Yield 2026 *
3.12%
Yield 2027 * 3.2%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.67%+10.34%+55.99%+161.79% 1,07700Cr
+0.89%+11.04%+68.13%+56.50% 61TCr
-0.02%+10.45%+36.86%+90.68% 45TCr
+1.86%+4.85%+28.17%+22.04% 33TCr
-0.14%+7.58%+41.28%+27.25% 29TCr
-0.06%+4.92%+31.23%+41.59% 29TCr
-0.96%+4.98%-28.37%-40.96% 21TCr
+0.07%+4.33%+28.81%+62.62% 19TCr
-1.60%+0.95%+13.70%+65.84% 16TCr
Average +0.09%+8.48%+30.65%+54.15% 40.18TCr
Weighted average by Cap. +0.39%+9.65%+41.65%+80.33%

Financials

2026 *2027 *
Net sales 1.48TCr 1.29TCr 1.19TCr 1.12TCr 2.1TCr 1,39700Cr 2.15TCr 14TCr 5.55TCr 69TCr 5.55TCr 5.43TCr 2,39200Cr 1.5TCr 1.32TCr 1.22TCr 1.14TCr 2.14TCr 1,42200Cr 2.19TCr 15TCr 5.65TCr 70TCr 5.65TCr 5.52TCr 2,43500Cr
Net income 1.3Cr 1.14Cr 1.05Cr 98.11L 1.85Cr 122.88Cr 1.89Cr 13Cr 4.88Cr 61Cr 4.88Cr 4.77Cr 210.48Cr 50Cr 44Cr 40Cr 38Cr 71Cr 4.7TCr 72Cr 483.97Cr 186.83Cr 2.32TCr 186.84Cr 182.74Cr 8.06TCr
Net Debt 1.22TCr 1.07TCr 985.09Cr 919.89Cr 1.73TCr 1,15200Cr 1.77TCr 12TCr 4.58TCr 57TCr 4.58TCr 4.48TCr 1,97300Cr 1.1TCr 965.83Cr 891.63Cr 832.62Cr 1.57TCr 1,04300Cr 1.6TCr 11TCr 4.14TCr 51TCr 4.14TCr 4.05TCr 1,78600Cr
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-